Dysregulation of protein kinase C activity in chemoresistant metastatic breast cancer cells.

abstract：:Individual response of disseminated cancer to chemotherapy is unpredictable. In vitro chemotherapy-induced apoptosis can be measured and might be a method to evaluate in vivo activity of tested drugs. In this report, tumor cells of a patient with signet cell carcinoma of the stomach and diffuse bone marrow infiltratio...

journal_title：Anti-cancer drugs

authors： Trojan J,Kim SZ,Engels K,Kriener S,Mitrou PS,Chow KU

更新日期：2005-01-01 00:00:00

abstract：:There is growing interest in the discovery of bioactive metabolites from endophytes as an alternative source of therapeutics. Identification of their therapeutic targets is essential in understanding the underlying mechanisms and enhancing the resultant therapeutic effects. As such, bioactive compounds produced by end...

journal_title：Anti-cancer drugs

authors： Hazalin NA,Lim SM,Cole AL,Majeed AB,Ramasamy K

更新日期：2013-09-01 00:00:00

abstract：:5-Fluorouracil, usually in combination with folinic acid, is widely used in the treatment of both colorectal and head and neck squamous cell cancer patients. Since 5-fluorouracil plus folinic acid and the antifolate thymidylate synthase inhibitor; raltitrexed have distinct mechanisms of action and toxicity profiles, w...

journal_title：Anti-cancer drugs

authors： Avallone A,Di Gennaro E,Bruzzese F,Laus G,Delrio P,Caraglia M,Pepe S,Comella P,Budillon A

更新日期：2007-08-01 00:00:00

abstract：:Hemolytic uremic syndrome (HUS) is a rare clinical and biological entity. HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens. Little information is available concerning the occurrence and outcome of this syndrome after administration of more recen...

journal_title：Anti-cancer drugs

authors： Gross M,Hiesse C,Kriaa F,Goldwasser F

更新日期：1999-07-01 00:00:00

abstract：:Salivary adenoid cystic carcinoma (SACC), which is one of the most common malignant tumors of the salivary glands, is associated with a poor long-term outcome. There are currently few therapeutic options for patients with SACC. Recent studies have shown the potential of the application of ultraviolet-C (UV-C) irradiat...

journal_title：Anti-cancer drugs

authors： Jiang Y,Ge XY,Liu SM,Zheng L,Huang MW,Shi Y,Fu J,Zhang JG,Li SL

更新日期：2014-10-01 00:00:00

abstract：:Two young adults that presented with intra-abdominal desmoplastic small cell tumors (DSCT) without any evidence of a primary site are described. Both cases share the clinical characteristic features of this rare tumor which include predominant intra-abdominal location as initial presentation, nesting pattern of growth...

journal_title：Anti-cancer drugs

authors： Liau CT,Yang TS,Wang CH,Hsueh S

更新日期：1996-02-01 00:00:00

abstract：:This phase I study was performed to assess the feasibility of combining cisplatin/etoposide (VP-16) with the arotinoid Ro 40-8757 and to determine the dose-limiting toxicity (DLT) of Ro 40-8757 in this combination. Patients with non-small cell lung cancer were eligible. Treatment consisted of Ro 40-8757 p.o. day 1-21,...

journal_title：Anti-cancer drugs

authors： van Zuylen L,Schellens JH,Goey SH,Pronk LC,de Boer-Dennert MM,Loos WJ,Ma J,Stoter G,Verweij J

更新日期：1999-04-01 00:00:00

abstract：:BPR0C305 is a novel N-substituted indolyl glyoxylamide previously reported with in-vitro cytotoxic activity against a panel of human cancer cells including P-gp-expressing multiple drug-resistant cell sublines. The present study further examined the underlying molecular mechanism of anticancer action and evaluated the...

journal_title：Anti-cancer drugs

authors： Li WT,Yeh TK,Song JS,Yang YN,Chen TW,Lin CH,Chen CP,Shen CC,Hsieh CC,Lin HL,Chao YS,Chen CT

更新日期：2013-11-01 00:00:00

abstract：:Thioredoxin (Trx) expression is increased in several human primary cancers associated with aggressive tumor growth and decreased patient survival, and the Trx/Trx reductase (TrxR) system therefore provides an attractive target for cancer drug development. Various gold(III) compounds with none, one, two or three carbon...

journal_title：Anti-cancer drugs

authors： Engman L,McNaughton M,Gajewska M,Kumar S,Birmingham A,Powis G

更新日期：2006-06-01 00:00:00

abstract：:Pancreatic and biliary tract carcinomas are very chemoresistant. After a first-line treatment with a gemcitabine-based regimen, no second-line scheme is consolidated in clinical practice. The aim of this study was to evaluate the toxicity and the activity of the FOLFIRI regimen as first-line or second-line chemotherap...

journal_title：Anti-cancer drugs

authors： Moretto R,Raimondo L,De Stefano A,Cella CA,Matano E,De Placido S,Carlomagno C

更新日期：2013-10-01 00:00:00

abstract：:Mitoxantrone is a DNA topoisomerase II poison commonly used for the treatment of hormone-refractory prostate cancer. The risk of secondary leukaemia is well described after mitoxantrone treatment in breast cancer and multiple sclerosis. Recent improvements of systemic chemotherapy increased the median survival in pati...

journal_title：Anti-cancer drugs

authors： Martinez V,Mir O,Dômont J,Bouscary D,Goldwasser F

更新日期：2007-02-01 00:00:00

abstract：:Magnesium wasting is a frequent side effect of epidermal growth factor receptor (EGFR)-antibody treatment as magnesium-absorption mechanisms are dependent on EGFR signaling. EGFR-inhibition results in decreased renal reabsorption. There is evidence that hypomagnesemia during cetuximab treatment correlates with respons...

journal_title：Anti-cancer drugs

authors： Schulz C,Heinemann V,Heinrich K,Haas M,Holch JW,Fraccaroli A,Held S,von Einem JC,Modest DP,Fischer von Weikersthal L,Kullmann F,Moehler M,Scheithauer W,Jung A,Stintzing S

更新日期：2020-09-01 00:00:00

abstract：:Our previous studies have demonstrated the in-vitro and in-vivo targeting of a generation-5 (G5) dendrimer-based multifunctional conjugate, which used folic acid (FA) as the targeting agent and methotrexate (MTX) as the chemotherapeutic drug. For the synthesized G5-FA-MTX nanodevice conjugate to be clinically applicab...

journal_title：Anti-cancer drugs

authors： Myc A,Douce TB,Ahuja N,Kotlyar A,Kukowska-Latallo J,Thomas TP,Baker JR Jr

更新日期：2008-02-01 00:00:00

abstract：:Studies have shown that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells. However, breast cancer cells are generally resistant to TRAIL. In the present study, we explored the effect of bufalin on TRAIL-induced breast cancer cell apoptosis. The results showed...

journal_title：Anti-cancer drugs

authors： Yan S,Qu X,Xu L,Che X,Ma Y,Zhang L,Teng Y,Zou H,Liu Y

更新日期：2014-07-01 00:00:00

abstract：:Dihydroartemisinin (DHA), a semisynthetic derivative of artemisinin, has recently shown antitumor activity in various cancer cells. Its effect on pancreatic cancer is, however, unknown and the mechanism is unclear. The study aims to investigate its antitumor activity and underlying mechanisms in human pancreatic cance...

journal_title：Anti-cancer drugs

authors： Chen H,Sun B,Pan S,Jiang H,Sun X

更新日期：2009-02-01 00:00:00

abstract：:Apalutamide (ARN-509) is an antiandrogen that binds selectively to androgen receptors (AR) and does not show antagonist-to-agonist switch like bicalutamide. We compared the activity of ARN versus bicalutamide on prostate cancer cell lines. The 22Rv1, PC3, and DU145 cell lines were used to study the effect of ARN and b...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Kakouratos C,Kalamida D,Mitrakas A,Pouliliou S,Xanthopoulou E,Papadopoulou E,Fasoulaki V,Giatromanolaki A

更新日期：2018-04-01 00:00:00

abstract：:Interleukin-12 (IL-12) has important immunomodulatory effects on T and natural killer (NK) cells that might be exploited in anticancer treatment. Murine IL-12 models have shown antimetastatic and antitumor effects against murine tumors in vivo. Data on the effects of human IL-12 on human tumors are confined to 51Cr-re...

journal_title：Anti-cancer drugs

authors： Izquierdo MA,Degen D,Sypek JP,Von Hoff DD

更新日期：1996-05-01 00:00:00

abstract：:In our institution, 103 glioblastoma multiforme (GBM) patients aged from 55 to 83 years were treated since November 1994 as follows. All patients underwent surgical intervention (gross total resection, n = 35; subtotal resection, n = 38; stereotactic biopsy, n = 30). Subsequently all patients were offered radiotherapy...

journal_title：Anti-cancer drugs

authors： Piribauer M,Fazeny-Dörner B,Rössler K,Ungersböck K,Czech T,Killer M,Dieckmann K,Birner P,Prayer D,Hainfellner J,Muhm M,Marosi C

更新日期：2003-02-01 00:00:00

abstract：:Analog II (1,1-dichloro-cis-2,3-diarylcyclopropane), previously shown to be a pure antiestrogen in mice, was examined for potential antitumor activity on human breast cancer cells in culture. In this study, Analog II produced a dose-related antiproliferative effect on the growth of estrogen receptor (ER)-positive MCF-...

journal_title：Anti-cancer drugs

authors： Jain PT,Rajah TT,Pento JT

更新日期：1997-11-01 00:00:00

abstract：:Triterpenoids are structurally diverse organic compounds, characterized by a basic backbone modified in multiple ways, allowing the formation of more than 20 000 naturally occurring triterpenoid varieties. Several triterpenoids, including ursolic and oleanolic acid, betulinic acid, celastrol, pristimerin, lupeol, and ...

journal_title：Anti-cancer drugs

authors： Petronelli A,Pannitteri G,Testa U

更新日期：2009-11-01 00:00:00

abstract：:Lung cancer is considered the number one killer among all cancers. Recent observations have altered the treatment paradigm for non-small-cell lung cancer (NSCLC). The discovery of activating mutations in the epidermal growth factor receptor and anaplastic lymphoma kinase positivity has made personalized treatment for ...

journal_title：Anti-cancer drugs

authors： Petrosyan F,Daw H,Haddad A,Spiro T

更新日期：2012-11-01 00:00:00

abstract：:Antimicrobial peptides of the cathelicidin family play a central role in the host defense system. Our group has reported previously that cathelicidin-related or cathelicidin-modified antimicrobial peptides, such as FF/CAP-18, have antiproliferative effects on the squamous cell carcinoma cell line SAS-H1 and colon canc...

journal_title：Anti-cancer drugs

authors： Kuroda K,Fukuda T,Okumura K,Yoneyama H,Isogai H,Savage PB,Isogai E

更新日期：2013-09-01 00:00:00

abstract：:The epithelial-mesenchymal transition (EMT) plays an important role in inducing cancer metastasis. Baicalin, a flavone derivative isolated from Scutellaria spp., shows a series of pharmacological and physiological activities. However, the possible role of baicalin in the EMT is unclear. In this study, we attempted to ...

journal_title：Anti-cancer drugs

authors： Wang Y,Wang H,Zhou R,Zhong W,Lu S,Ma Z,Chai Y

更新日期：2017-07-01 00:00:00

abstract：:The aim of this study was to investigate in a randomized trial the activity of perioperative chemotherapy in patients treated with preoperative chemotherapy for locally advanced breast cancer and to compare it with the preoperative chemotherapy alone. Patients with cT2-3 N0-2 M0 histologically proven breast cancer, wi...

journal_title：Anti-cancer drugs

authors： Rocca A,Peruzzotti G,Ghisini R,Viale G,Veronesi P,Luini A,Intra M,Pietri E,Curigliano G,Giovanardi F,Maisonneuve P,Goldhirsch A,Colleoni M

更新日期：2006-11-01 00:00:00

abstract：:Imatinib mesylate is a specific inhibitor of the Bcr-Abl protein tyrosine kinase that competes with ATP for its specific binding site in the kinase domain. It has activity against platelet-derived growth factor receptor alpha and beta (PDGFR-alpha and -beta), and c-kit, the receptor for stem cell factor. We have used ...

journal_title：Anti-cancer drugs

authors： Knight LA,Di Nicolantonio F,Whitehouse PA,Mercer SJ,Sharma S,Glaysher S,Hungerford JL,Hurren J,Lamont A,Cree IA

更新日期：2006-07-01 00:00:00

abstract：:Topoisomerase IIalpha (Topo IIalpha) is an essential nuclear enzyme with a role in the maintenance of DNA topology. Topo IIalpha is a target for several anticancer drugs and the levels of activity of this enzyme have been implicated in the development of drug resistance. Our objective was to identify regulatory transc...

journal_title：Anti-cancer drugs

authors： Allen KA,Williams AO,Isaacs RJ,Stowell KM

更新日期：2004-04-01 00:00:00

abstract：:Trifluorothymidine (TFT) is a fluorinated thymidine analog that after conversion to its monophosphate derivative can inhibit thymidylate synthase (TS) and be incorporated into DNA. TFT is a good substrate for thymidine phosphorylase (TP), and the combination of TFT and a TP inhibitor (TPI), called TAS-102, has been de...

journal_title：Anti-cancer drugs

authors： Temmink OH,de Bruin M,Comijn EM,Fukushima M,Peters GJ

更新日期：2005-03-01 00:00:00

abstract：:We have established estrogen-independent and antiestrogen-resistant cell lines from hormone-dependent MCF-7 breast cancer cells by long-term culture in the absence of estrogen, or in the presence of antiestrogen toremifene, respectively. By using a cDNA microarray we compared gene expression profiles among estrogen-in...

journal_title：Anti-cancer drugs

authors： Pennanen PT,Sarvilinna NS,Ylikomi TJ

更新日期：2009-01-01 00:00:00

abstract：:Monoclonal antibodies such as rituximab and alemtuzumab show considerable therapeutic efficacy in chronic lymphocytic leukaemia (CLL). Aiming to further improve antineoplastic efficacy, the trifunctional bispecific antibody FBTA05 was developed. FBTA05 is thought to function by simultaneously binding B cells and T cel...

journal_title：Anti-cancer drugs

authors： Boehrer S,Schroeder P,Mueller T,Atz J,Chow KU

更新日期：2011-07-01 00:00:00

abstract：:Leiomyosarcomas represent the most common variant of uterine sarcomas, and are also considered to be the least chemosensitive. To date, adriamycin and ifosfamide are believed to be the most effective drugs for its treatment, in addition to docetaxel and gemcitabine. Recently, the introduction of trabectedin has provid...

journal_title：Anti-cancer drugs

authors： Tavella K,Villanucci A,Vannini L,Lavacchi D,Montelatici S,Amunni G,Mazzei T

更新日期：2017-04-01 00:00:00